- Home
- ANGH vs KALA Comparison
ANGH vs KALA Comparison
Compare ANGH & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- KALA
- Stock Information
- Founded
- ANGH 2012
- KALA 2009
- Country
- ANGH United Arab Emirates
- KALA United States
- Employees
- ANGH N/A
- KALA N/A
- Industry
- ANGH Telecommunications Equipment
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- KALA Health Care
- Exchange
- ANGH Nasdaq
- KALA Nasdaq
- Market Cap
- ANGH 32.1M
- KALA 26.2M
- IPO Year
- ANGH N/A
- KALA 2017
- Fundamental
- Price
- ANGH $0.43
- KALA $7.36
- Analyst Decision
- ANGH
- KALA Strong Buy
- Analyst Count
- ANGH 0
- KALA 3
- Target Price
- ANGH N/A
- KALA $14.00
- AVG Volume (30 Days)
- ANGH 2.8M
- KALA 204.0K
- Earning Date
- ANGH 08-05-2025
- KALA 08-05-2025
- Dividend Yield
- ANGH N/A
- KALA N/A
- EPS Growth
- ANGH N/A
- KALA N/A
- EPS
- ANGH N/A
- KALA N/A
- Revenue
- ANGH $78,093,405.00
- KALA N/A
- Revenue This Year
- ANGH N/A
- KALA N/A
- Revenue Next Year
- ANGH N/A
- KALA N/A
- P/E Ratio
- ANGH N/A
- KALA N/A
- Revenue Growth
- ANGH 88.72
- KALA N/A
- 52 Week Low
- ANGH $0.42
- KALA $2.92
- 52 Week High
- ANGH $0.99
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- ANGH 52.76
- KALA 74.24
- Support Level
- ANGH $0.44
- KALA $5.35
- Resistance Level
- ANGH $0.71
- KALA $8.49
- Average True Range (ATR)
- ANGH 0.07
- KALA 0.79
- MACD
- ANGH 0.01
- KALA 0.24
- Stochastic Oscillator
- ANGH 38.70
- KALA 97.13
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.